Cargando…

VEGF-R2/Caveolin-1 Pathway of Undifferentiated ARPE-19 Retina Cells: A Potential Target as Anti-VEGF-A Therapy in Wet AMD by Resvega, an Omega-3/Polyphenol Combination

Age-related macular degeneration (AMD) is one of the main causes of deterioration in vision in adults aged 55 and older. In spite of therapies, the progression of the disease is often observed without reverse vision quality. In the present study, we explored whether, in undifferentiated ARPE-19 reti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Courtaut, Flavie, Scagliarini, Alessandra, Aires, Virginie, Cornebise, Clarisse, Pais de Barros, Jean-Paul, Olmiere, Céline, Delmas, Dominique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234996/ https://www.ncbi.nlm.nih.gov/pubmed/34205419 http://dx.doi.org/10.3390/ijms22126590

Ejemplares similares

Resvega, a Nutraceutical Preparation, Affects NFκB Pathway and Prolongs the Anti-VEGF Effect of Bevacizumab in Undifferentiated ARPE-19 Retina Cells
por: Sghaier, Randa, et al.
Publicado: (2022)

Red Wine Extract Inhibits VEGF Secretion and Its Signaling Pathway in Retinal ARPE-19 Cells to Potentially Disrupt AMD
por: Cornebise, Clarisse, et al.
Publicado: (2020)

RESVEGA, a Nutraceutical Omega-3/Resveratrol Supplementation, Reduces Angiogenesis in a Preclinical Mouse Model of Choroidal Neovascularization
por: Courtaut, Flavie, et al.
Publicado: (2021)

New Highlights of Resveratrol: A Review of Properties against Ocular Diseases
por: Delmas, Dominique, et al.
Publicado: (2021)

Anti-VEGF Treatment Strategies for Wet AMD
por: Kovach, Jaclyn L., et al.
Publicado: (2012)

Resvega Alleviates Hydroquinone-Induced Oxidative Stress in ARPE-19 Cells
por: Bhattarai, Niina, et al.
Publicado: (2020)

Anti-VEGF Drugs Influence Epigenetic Regulation and AMD-Specific Molecular Markers in ARPE-19 Cells
por: Hamid, Mohamed A., et al.
Publicado: (2021)

Red Wine Extract Prevents Oxidative Stress and Inflammation in ARPE-19 Retinal Cells
por: Cornebise, Clarisse, et al.
Publicado: (2023)

Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD
por: Batioglu, Figen, et al.
Publicado: (2015)

Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD
por: Reid, Christopher A., et al.
Publicado: (2018)

Caveolin-1 Down-Regulation Reduces VEGF-A Secretion Induced by IGF-1 in ARPE-19 Cells
por: Puddu, Alessandra, et al.
Publicado: (2021)

New Therapies of Neovascular AMD—Beyond Anti-VEGFs
por: Yerramothu, Praveen
Publicado: (2018)

Bevacizumab in Wet AMD treatment: A tribute to the thirteen years of experience from the beginning of the anti-VEGF era in Romania
por: Stanca, Horia T., et al.
Publicado: (2019)

VEGF Profile in Early Undifferentiated Arthritis Cohort
por: Sakalyte, Regina, et al.
Publicado: (2022)

New Therapies of Neovascular AMD beyond Anti-VEGF Injections
por: Gahn, Greggory M., et al.
Publicado: (2018)

Anti-VEGF Therapy and the Retina: An Update
por: Tah, Vikas, et al.
Publicado: (2015)

Subretinal recombinant tissue plasminogen activator and pneumatic displacement for the management of subretinal hemorrhage occurring after anti-VEGF injections for wet AMD
por: Tognetto, Daniele, et al.
Publicado: (2011)

Documentation of adverse events in non-commercial trials of intravitreal injection of anti-VEGF drugs to treat wet age-related macular degeneration (AMD)
por: Reeves, Barnaby C, et al.
Publicado: (2011)

Ginsenoside-Rb1 Induces ARPE-19 Proliferation and Reduces VEGF Release
por: Betts, Brandi S., et al.
Publicado: (2012)

Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD
por: Fassnacht-Riederle, Heidi, et al.
Publicado: (2014)

Anti-VEGF intervention in neovascular AMD: benefits and risks restated as natural frequencies
por: Clearkin, Louis, et al.
Publicado: (2019)

Switching anti-VEGF agent for wet AMD: evaluation of impact on visual acuity, treatment frequency and retinal morphology in a real-world clinical setting
por: Granstam, Elisabet, et al.
Publicado: (2021)

Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis
por: Wu, Mingxing, et al.
Publicado: (2017)

VEGF Triggers the Activation of Cofilin and the Arp2/3 Complex within the Growth Cone
por: Schlau, Matthias, et al.
Publicado: (2018)

VEGF with AMD3100 endogenously mobilizes mesenchymal stem cells and improves fracture healing
por: Meeson, Richard, et al.
Publicado: (2018)

A serum metabolomics study of patients with nAMD in response to anti-VEGF therapy
por: Gao, Yan, et al.
Publicado: (2020)

Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients
por: Skelly, Adrian, et al.
Publicado: (2019)

Topographical Analysis of the Choriocapillaris Reperfusion After Loading Anti-VEGF Therapy in Neovascular AMD
por: Viggiano, Pasquale, et al.
Publicado: (2022)

The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD
por: Faatz, Henrik, et al.
Publicado: (2022)

Profiles of Cytokines Secreted by ARPE-19 Cells Exposed to Light and Incubated with Anti-VEGF Antibody
por: Sato, Tomohito, et al.
Publicado: (2021)

Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD
por: Moraru, Andreea, et al.
Publicado: (2017)

“What should I inject next?” Challenging treatment decisions in the multiple anti-VEGF: a review of publications exploring anti-VEGF switching for nAMD
por: Pikkel, Joseph, et al.
Publicado: (2017)

Epimacular brachytherapy for wet AMD: current perspectives
por: Casaroli-Marano, Ricardo P, et al.
Publicado: (2014)

ARPE-19-derived VEGF-containing exosomes promote neovascularization in HUVEC: the role of the melanocortin receptor 5
por: Maisto, Rosa, et al.
Publicado: (2019)

Phosphorylation of STAT3 and ERBB2 mediates hypoxia-induced VEGF release in ARPE-19 cells
por: Hwang, Soohyun, et al.
Publicado: (2020)

Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD
por: Tsilimbaris, Miltiadis K., et al.
Publicado: (2016)

Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review
por: Khanna, Saira, et al.
Publicado: (2019)

The effect of systemic levels of TNF-alpha and complement pathway activity on outcomes of VEGF inhibition in neovascular AMD
por: Khan, Adnan H., et al.
Publicado: (2021)

Psychological impact of anti-VEGF treatments for wet macular degeneration—a review
por: Senra, Hugo, et al.
Publicado: (2016)

Aflibercept in wet AMD: specific role and optimal use
por: Semeraro, F, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4dups2u55o32utvqacjcn6e6bm